Unlike CAR-T cells—which depend on perforin/granzyme-mediated cytotoxicity and tend to have limited effectiveness (5–20%) in solid tumours—CAR-Ms eliminate tumours via phagocytosis and release pro-inflammatory cytokines like TNF-α and IL-12, promoting infiltration of endogenous T-cells. Here, PRF1 is linked to neoplasm.